Study of Arimoclomol in Inclusion Body Myositis (IBM)

Status Completed

Clinical Trial Summary

Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.

Clinical Trial Description

A Phase 2/3, randomized, double-blind, placebo-controlled, international, 20-month intervention study in patients with IBM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02753530
Study type	Interventional
Source	ZevraDenmark
Contact
Status	Completed
Phase	Phase 2
Start date	August 16, 2017
Completion date	January 11, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00769860` - Arimoclomol in Sporadic Inclusion Body Myositis	Phase 2/Phase 3
Completed	`NCT01165008` - Anakinra in Myositis	Phase 2/Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Active, not recruiting	`NCT05046821` - Sporadic Inclusion Body Myositis Natural History Study
Recruiting	`NCT06153108` - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting	`NCT04659031` - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)	Phase 1
Completed	`NCT03440034` - Study of Pioglitazone in Sporadic Inclusion Body Myositis	Phase 1
Terminated	`NCT04049097` - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial	Phase 3
Completed	`NCT00001261` - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies	Phase 2
Recruiting	`NCT05272969` - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed	`NCT01734369` - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting	`NCT04975841` - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells	N/A
Recruiting	`NCT00017914` - Adult and Juvenile Myositis
Completed	`NCT00917956` - Lithium in Inclusion Body Myositis (IBM)	N/A
Completed	`NCT03633318` - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Recruiting	`NCT04789070` - Phase III Trial of Sirolimus in IBM	Phase 3
Active, not recruiting	`NCT05721573` - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis	Phase 2/Phase 3
Recruiting	`NCT05032131` - Cell Therapy for IBM by Muscle Injection of ADSVF	Phase 1
Completed	`NCT03299335` - Molecular Profile of the Evolution of Inclusion Body Myositis	N/A
Completed	`NCT04421677` - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Phase 1